Our Firm is following this litigation very closely, as we have heard from numerous individuals concerned about the alleged connection between the use of Risperdal and male breast growth.
New York, New York (PRWEB) November 13, 2013
At least 250 Risperdal lawsuits (http://www.therisperdallawsuit.com/), many involving allegations that the use of the antipsychotic drug caused boys to develop gynecomastia, or male breast growth, are currently pending in a litigation underway in Pennsylvania’s Philadelphia Court of Common Pleas, Bernstein Liebhard LLP reports. According to court documents, while a few of the cases involving Risperdal gynecomastia allegations filed in the litigation have settled, the majority of such claims remain unresolved. (Risperdal Litigation, case number 100300296)
“Our Firm is following this litigation very closely, as we have heard from numerous individuals concerned about the alleged connection between the use of Risperdal and male breast growth,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Risperdal lawsuit consultations to any individual who may have developed gynecomastia due to Risperdal.
Known as an atypical antipsychotic, Risperdal is currently approved for the treatment of schizophrenia in adults and adolescents, as well as bipolar disorder in adults and children ages 10-to-17. Risperdal is also approved to treat irritability in children (5-to-16 years of age) with autistic disorder.* There are also indications that use of Risperdal to treat ADHD is also on the rise, though it’s not been approved for this purpose.**
On November 4th, the U.S. Department of Justice announced that it had reached an agreement with Johnson & Johnson and its Janssen Pharmaceuticals Inc. unit by which the companies will pay $2.2 billion to settle a government probe into the marketing of some of their drugs, including Risperdal. According to a press release issued by the Justice Department, the settlement includes $4.85 million in criminal fines, and $1.72 billion in civil penalties. Among other things, the agreement resolves charges that Johnson & Johnson misbranded Risperdal and promoted off-label use of the drug for children, elderly nursing home patients, and those with mental disabilities.
Court records indicate that in October 2012, Johnson & Johnson and Janssen agreed to settle five claims involving Risperdal and gynecomastia that had been filed in the Pennsylvania litigation. Among other things, the lawsuits alleged that the companies knew use of the drug could lead to male breast development, and that its sales reps were trained to downplay this potential Risperdal side effect. The Plaintiffs also alleged that Risperdal was illegally marketed for use in children.***
Alleged victims of Risperdal and male breast growth may be entitled to compensation for medical bills, lost wages, pain and suffering and more. Learn More about Risperdal and gynecomastia at Bernstein Liebhard LLP’s website. For a free case review, please contact the Firm by calling 800-511-5092.
*accessdata.fda.gov/drugsatfda_docs/label/2009/020272s056,020588s044,021346s033,021444s03lbl.pdf, Risperdal Prescribing Information, FDA, 2009
**health.usnews.com/health-news/news/articles/2012/08/07/more-kids-taking-antipsychotics-for-adhd-study, U.S. News & World Report, August 7, 2012
***bloomberg.com/news/2012-10-04/johnson-johnson-agrees-to-settle-five-rispersal-suits.html, Bloomberg.com, October 4, 2012
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com